Leplow, Bernd http://orcid.org/0000-0002-6976-4194
Renftle, Daniela
Thomas, Mareike
Michaelis, Katja
Solbrig, Susanne
Maetzler, Walter
Berg, Daniela
Liepelt-Scarfone, Inga
Funding for this research was provided by:
Martin-Luther-Universität Halle-Wittenberg
Article History
Received: 26 September 2022
Accepted: 4 January 2023
First Online: 20 January 2023
Declarations
:
: B. Leplow has nothing to disclose. D. Renftle has nothing to disclose. M. Thomas has nothing to disclose. K. Michaelis has nothing to disclose. S. Solbrig has nothing to disclose. W. Maetzler reports grant from the European Union, the German Federal Ministry of Education of Research, German Research Council, Michael J. Fox Foundation, Robert Bosch Foundation, Neuroalliance, Lundbeck, Sivantos and Janssen, outside the submitted work. He received speaker honoraria from Abbvie, Bayer, GlaxoSmithKline, Licher MT, Neuro-Kolleg Online-Live, Rölke Pharma, Takeda and UCB, was invited to Advisory Boards of Abbvie, Biogen, Kyowa Kirin, Lundbeck and Market Access & Pricing Strategy GmbH, is an advisory board member of the Critical Path for Parkinson's Consortium, and an editorial board member of Geriatric Care. He serves as the co-chair of the MDS Technology Task Force. D. Berg reports grants from Janssen Research and Development, a division of Janssen Pharmaceutica N.V. related to the conduct of this study; grants from German Research Foundation (DFG), German Parkinson’s Disease Association (dPV), German Ministry for Education and Research (BMBF), Parkinson Fonds Deutschland gGmbH, UCB Pharma GmbH, EU, Novartis Pharma GmbH, Lundbeck, Damp foundation, outside the submitted work. She received speaker honoraria from AbbVie, Biogen, BIAL, UCB Pharma GmbH Zambon, Desitin and was invited to Advisory Boards for Biogen, BIAL, UCB Pharma GmbH, Zambon. I. Liepelt-Scarfone reports grants from Janssen Research and Development, a division of Janssen Pharmaceutica N.V. related to the conduct of this study; grants from the Michael J. Fox Foundation during the conduct of the study, European Commission, H2020-TWINN-2015, International Parkinson Fonds (Deutschland) GmbH (IPD), Novartis, German Ministry for Education and Research (BMBF), outside the submitted work.